Treatment sequences for advanced renal cell carcinoma: A health economic assessment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment sequences for advanced renal cell carcinoma: A health economic assessment
Authors
Keywords
Renal cell carcinoma, Cancer treatment, Cost-effectiveness analysis, Health economics, Sequence analysis, Drug therapy, Survival analysis, Phase III clinical investigation
Journal
PLoS One
Volume 14, Issue 8, Pages e0215761
Publisher
Public Library of Science (PLoS)
Online
2019-08-30
DOI
10.1371/journal.pone.0215761
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma
- (2018) Michal Sarfaty et al. EUROPEAN UROLOGY
- Updates to the Management of Kidney Cancer
- (2018) Eric Jonasch Journal of the National Comprehensive Cancer Network
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) B. Escudier et al. ANNALS OF ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics
- (2016) J. Jaime Caro PHARMACOECONOMICS
- A two-stage approach for dynamic prediction of time-to-event distributions
- (2016) Xuelin Huang et al. STATISTICS IN MEDICINE
- Kidney Cancer, Version 3.2015
- (2015) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Metastatic renal cell cancer
- (2014) Finn Rasmussen CANCER IMAGING
- Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US
- (2014) Allison Perrin et al. JOURNAL OF MEDICAL ECONOMICS
- Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib
- (2013) Brian I. Rini et al. Clinical Genitourinary Cancer
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single-center experience with 31 patients
- (2012) Bruno Neri et al. INTERNATIONAL JOURNAL OF UROLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Epidemiology and risk factors for kidney cancer
- (2010) Wong-Ho Chow et al. Nature Reviews Urology
- How Do Cost-Effectiveness Analyses Inform Reimbursement Decisions for Oncology Medicines in Canada? The Example of Sunitinib for First-Line Treatment of Metastatic Renal Cell Carcinoma
- (2010) Isabelle Chabot et al. VALUE IN HEALTH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma
- (2008) Edit Remák et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started